ATE220677T1 - Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung - Google Patents

Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung

Info

Publication number
ATE220677T1
ATE220677T1 AT94906381T AT94906381T ATE220677T1 AT E220677 T1 ATE220677 T1 AT E220677T1 AT 94906381 T AT94906381 T AT 94906381T AT 94906381 T AT94906381 T AT 94906381T AT E220677 T1 ATE220677 T1 AT E220677T1
Authority
AT
Austria
Prior art keywords
alkyl
suitable substituent
pct
pyrazolotriazines
interleukin
Prior art date
Application number
AT94906381T
Other languages
German (de)
English (en)
Inventor
Yoshio Kawai
Hitoshi Yamazaki
Hirokazu Tanaka
Teruo Oku
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE220677T1 publication Critical patent/ATE220677T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT94906381T 1993-02-26 1994-02-09 Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung ATE220677T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939303993A GB9303993D0 (en) 1993-02-26 1993-02-26 New heterocyclic derivatives
PCT/JP1994/000213 WO1994019350A1 (en) 1993-02-26 1994-02-09 Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity

Publications (1)

Publication Number Publication Date
ATE220677T1 true ATE220677T1 (de) 2002-08-15

Family

ID=10731142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94906381T ATE220677T1 (de) 1993-02-26 1994-02-09 Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung

Country Status (20)

Country Link
US (1) US5670503A (OSRAM)
EP (1) EP0686156B1 (OSRAM)
JP (1) JP3569917B2 (OSRAM)
KR (1) KR100313615B1 (OSRAM)
CN (1) CN1041929C (OSRAM)
AT (1) ATE220677T1 (OSRAM)
AU (1) AU681625B2 (OSRAM)
CA (1) CA2156919A1 (OSRAM)
DE (1) DE69430988T2 (OSRAM)
DK (1) DK0686156T3 (OSRAM)
ES (1) ES2176235T3 (OSRAM)
GB (1) GB9303993D0 (OSRAM)
HU (1) HUT70832A (OSRAM)
IL (1) IL108562A (OSRAM)
MX (1) MX9401408A (OSRAM)
PT (1) PT686156E (OSRAM)
RU (1) RU2124517C1 (OSRAM)
TW (1) TW260669B (OSRAM)
WO (1) WO1994019350A1 (OSRAM)
ZA (1) ZA94787B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP4380803B2 (ja) 1997-06-12 2009-12-09 アベンテイス・フアルマ・リミテツド イミダゾリル−環式アセタール
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6455528B1 (en) 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (en) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
AU6729900A (en) * 1999-08-31 2001-03-26 Fujisawa Pharmaceutical Co., Ltd. Organ preservatives
RU2264403C2 (ru) * 1999-11-10 2005-11-20 Орто-Макнейл Фармасьютикал, Инк. Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
JP2003514899A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション CSBP/p38キナーゼ阻害剤としての3,4‐ジヒドロ−(1H)−キナゾリン−2−オン化合物
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション CSBP/p38キナーゼ阻害剤としての3,4‐ジヒドロ−(1H)キナゾリン−2−オン化合物
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
RU2316556C2 (ru) * 2000-11-17 2008-02-10 Бристол-Маерс Сквибб Компани СПОСОБЫ ЛЕЧЕНИЯ СОСТОЯНИЙ, ОБУСЛОВЛЕННЫХ p38 КИНАЗАМИ, И ПИРРОЛОТРИАЗИНОВЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ
JP2004518731A (ja) * 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ, インコーポレイテッド 三環式crfレセプターアンタゴニスト
NZ528525A (en) 2001-05-24 2005-10-28 Lilly Co Eli Novel pyrrole derivatives as pharmaceutical agents
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4494205B2 (ja) * 2002-08-26 2010-06-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
ATE490244T1 (de) * 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
AU2005252183B2 (en) * 2004-06-04 2008-07-17 Merck Sharp & Dohme Corp. Pyrazole derivatives, compositions containing such compounds and methods of use
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
CA2614537A1 (en) 2005-07-26 2007-02-08 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20110195962A1 (en) * 2007-08-16 2011-08-11 Alcon Research, Ltd. Use of multi-pharmacophore compounds to treat nasal disorders
JP2010540451A (ja) * 2007-09-20 2010-12-24 ワイス・エルエルシー ピラゾロ[5,1−c][1,2,4]トリアジン、その調製法および使用法
CN101441972B (zh) 2007-11-23 2011-01-26 鸿富锦精密工业(深圳)有限公司 场发射像素管
CN101441969B (zh) 2007-11-23 2010-07-28 清华大学 场发射像素管
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502178A (ja) * 1990-12-31 1994-03-10 藤沢薬品工業株式会社 イミダゾトリアジン誘導体
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
KR100313615B1 (ko) 2002-05-30
AU6010894A (en) 1994-09-14
ZA94787B (en) 1994-09-08
PT686156E (pt) 2002-12-31
DK0686156T3 (da) 2002-11-11
RU2124517C1 (ru) 1999-01-10
ES2176235T3 (es) 2002-12-01
KR960701055A (ko) 1996-02-24
CN1041929C (zh) 1999-02-03
CA2156919A1 (en) 1994-09-01
GB9303993D0 (en) 1993-04-14
DE69430988T2 (de) 2002-11-28
JPH08507056A (ja) 1996-07-30
EP0686156A1 (en) 1995-12-13
IL108562A (en) 1997-06-10
HUT70832A (en) 1995-11-28
EP0686156B1 (en) 2002-07-17
IL108562A0 (en) 1994-05-30
TW260669B (OSRAM) 1995-10-21
HU9402459D0 (en) 1994-11-28
CN1120840A (zh) 1996-04-17
WO1994019350A1 (en) 1994-09-01
JP3569917B2 (ja) 2004-09-29
MX9401408A (es) 1994-08-31
US5670503A (en) 1997-09-23
DE69430988D1 (de) 2002-08-22
AU681625B2 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
ATE220677T1 (de) Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung
HU9601685D0 (en) 4,5-diaryloxazole derivatives
TW262471B (OSRAM)
MX9800577A (es) Derivados de 4,5-diaril oxazol.
FI954609A0 (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
GB9300194D0 (en) Piperazine derivatives
GR3035621T3 (en) New pyrimidone derivatives with antifungal activity
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
GB9602029D0 (en) New heterocyclic compounds
EP0572635A4 (fr) Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.
IL108258A0 (en) Piperazine derivates, their preparation and pharmaceutical compositions containing them
GB9313330D0 (en) New compound and its preparation
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE155791T1 (de) Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE255102T1 (de) Benzothiophenderivate, ihre herstellung und verwendung als urokinase-inhibitoren
DE69124519D1 (de) Spiro[cycloalkylbenzen-1,1'-(1',2',3',4'-tetrahydroisoquinoline)] mit neuroprotektiven eigenschaften
ATE219671T1 (de) Verwendung von hydroxyprolinen zur herstellung eines arzneimittels zur hemmung der leukozyteninvasion in gewebe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee